Antifungal activity evaluation of different propolis extracts;Obtenção de extratos de própolis sob diferentes condições e avaliação de sua atividade antifúngica

Revista Brasileira de Farmacognosia

Volumn 17, Issue 3, 2007, Pages 388-395

  Longhini, Renata ^a   Raksa, Sheila M ^a   Oliveira, Ana Carla P ^a   Svidzinski, Terezinha I E ^a   Franco, Selma L ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Antifungal activity; Apis mellifera; Extract optimization; Onychomycosis; Propolis

Indexed keywords

EID: 35248821379     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0102-695x2007000300015     Document Type: Article

References (28)

1. Araujo AJG, Bastos OMP, Souza MAJ, Oliveira JC 2003. Onicomicoses por fungos emergentes: análise clínica, diagnóstico laboratorial e revisão. An Bras Dermatol 78: 445-455.
2. Burdock GA 1998. Review of the biological properties and toxicity of bee propolis. Food Chem Toxicol 36: 347-363.
3. Bruschi ML, Franco SL, Gremião MPD 2003. Applications of a HPLC method in analysis of propolis extract. J Liq Chromatogr Relat Technol 26: 14, 2381-2391.
4. Chan MK, Chong LY, + Achilles Project Working Group in Hong Kong. 2002. A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong J Am Pediatr Med Assoc 92: 450-456.
5. Cushnie TPT, Lamb AJ 2005. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 26: 343-356.
6. De Castro, SL 2001. Propolis: biological and pharmacological activities, Arbs Amn Rev Biomed Sci 3: 49-83.
7. Deutsches Arzneibuch 1994. 10. ed. Stuttgart: Deutscher Apotheker.
8. Diemunsch A-M, Mathis C 1980. Labo-Pharma- Probémes et Techniques 294: 55-63.
9. Dorko E, Jautova J, Tkacikova L, Wantrubova A 2002. The frequency of Candida species in onychomycosis. Folia Microbiol 47: 727-773.
10. Elewski BE, Leyden J, Rinaldi MG, Atillasoy E 2002. Office practice-based confirmation of onychomycosis: a US nationwide prospective survey Arch Intern Med 162: 2133-2138.
11. Ellabib MS, Agaj M, Khalifa Z, Kavanagh K 2002. Yeasts of genus Candida are the dominant cause of onychomycosis in Libyan women but not men: results of a 2-year surveillance study. Brit J Dermatol 146: 1038-1041.
12. Farmacopéia Brasileira 1988. 4. ed., Ed. Atheneu, São Paulo. p.v.2.5., v.2.9., v.2.10, v.2.19.
13. Fernandes Jr A, Sugizaki, MF, Fogo ML, Funari SRC, Lopes CAM 1995. In vitro activity of propolis against bacterial and yeast pathogens isolated from human infections. J Venom Anim Toxins 1: 63-69.
14. Franco SL, Bruschi ML, Moura LPP, Bueno JH 2000. Caracterizaç ão farmacognóstica da própolis da região de Maringá. Rev Bras Farmacogn 9/10: 1-10.
15. Franco SL, Bueno JHF 1999. Otimização de processo extrativo de própolis. Infarma 11: 48-51.
16. Guilhermetti E, Kioshima ES, Shinobu C, Silva SC, Mota VA, Svidzinski TIE 2004 Medical micology: an emergent subject in clinical analysis. Rev Bras Anal Clin 36: 51-53.
17. Kujumgiev A, Tsvetkova I, Serkedijieva Y, Bankova V, Cristov R, Popov S 1999. Antibacterial, antifungal and antiviral activity of propolis of different geographic origin. J Ethnopharmacol 64: 235-240.
18. Larone DH 1995. Medically important fungi. A guide to identification, AMS Press, Washington.
19. Mello JCP, Petrovick PR 2000. Quality control of Baccharis trimera (Less.) DC. (Asteraceae) hydroalcoholic extracts. Acta Farma Bonaerense 19: 211-215.
20. Mercantini R, Marsella R, Moretto D 1996. Onychomycosis in Rome, Italy. Mycopathologia 136: 25-32.
21. National Committee for Clinical Laboratory Standards (NCCLS) 1997. Reference Method For Broth Dilution Antifungal Susceptibility Testing Of Yeasts; Approved Standard. Villanova, NCCLS, v.17, p. 28. M27-A.
22. Nieva Moreno MI, Isla MI, Cudmani NG, Vattuone MA, Sampietro AR 1999. Screening of antibacterial activity of Amaicha del Valle (Tucumán, Argentina) propolis. J Ethnopharmacol 68: 97-102.
23. Oliveira ACP, Shinobu CS, Longhini R, Franco SL, Svidizinski TIE 2006. Antifungal activity of propolis extract against yeasts isolated from onychomycosis lesions. Mem I Oswalde Cruz 101: 493-497.
24. Packer JF, Luz MMS 2007. Método para avaliação e pesquisa da atividade antimicrobiana de produtos de origem natural. Rev Bras Farmacogn 17: 102-107.
25. Soares AKA, Carmo GC, Quental DP, Nascimento DF, Bezerra FAF, Moraes MO, Moraes MEA 2006. Avaliação da segurança clínica de um fitoterápico contendo Mikania glomerata, Grindelia robusta, Copaifera officinalis, Myroxylon toluifera, Nasturtium officinale, própolis e mel em voluntários saudáveis. Rev Bras Farmacogn 16: 447-454.
26. Sonmez S, Kirilmaz L, Yucesoy M, Yücel B, Ylmaz B 2005. The effect of bee propolis on oral pathogens and human gingival fibroblast. J Ethnopharmacol 102: 371-376.
27. Sousa JPB, Furtado NAJC, Jorge R, Soares AEE, Bastes JK 2007. Perfis físico-químico e cromatográfico de amostras de própolis produzidas nas microrregiões de Franca (SP) e Passos (MG), Brasil. Rev Bras Farmacogn 17: 85-93.
28. Tavares JP, Martins IL, Vieira AS, Lima FAV, Bezerra FAF, Moraes MO, Moraes MEA 2006. Estudo de toxicologia clínica de um fitoterápico a base de associações de plantas, mel e própolis. Rev Bras Farmacogn 16: 350-356.